Impact Malaria

The Group's program confirms its commitment to the fight against malaria. Its involvement with this pathology goes back many years, mainly in Africa, where it is backed up by recognized scientific expertise and its relationships with the different players of the health sector.

A crucial involvement

The Group helps to fight against malaria through its research and its active support for development. Its very active commitment is unflagging. Like the World Health Organization's "Roll Back Malaria" program, the goal of sanofi-aventis is to control this disease and reduce the high mortality rate still associated with it.

Therapeutic arsenal

The Group puts at the disposal of the countries affected by this scourge a number of quinine derivatives - which remains the benchmark treatment for severe cases of malaria - in various presentations, as well as artemisinine derivatives. In response to the development of this disease, sanofi-aventis is also developing new therapeutic strategies, new anti-malaria compounds as well as new pharmaceutical products. These therapeutic combinaisons based on artemisinine are recommended by the World Health Organization.

Means adapted to the needs of each country

To intensify its fight against malaria, sanofi-aventis sets up programs adapted to the drug-resistance profiles of the different countries. It also works in close collaboration with governments, major international institutions, universities and research institutes.

An information and training strategy

Sanofi-aventis works to inform and train all the players in the field of health care:

• through dedicated training and educational programs for them and the general public
• via the internet site http://www.impact-malaria.com